Obesity Clinical Trial
Official title:
Increased Tidal Volume During Anaesthesia Compared to PEEP. Impact on Arterial Concentration of Sevoflurane, Oxygenation and Cardiac Output in a Randomised Clinical Study of Overweight Patients.
General anaesthesia impairs respiratory function in overweight patients. The investigators wanted to compare arterial concentration of sevoflurane and oxygen in overweight patients ventilated with increased tidal volume, or normal tidal volume with added 10 cm H2O PEEP.
Functional residual capacity (FRC) and pulmonary gas exchange decrease during induction of
general anaesthesia due to closure of airways and genesis of atelectasis. It has been
demonstrated that there is a correlation between body constitution and airway closure under
general anaesthesia with mechanical ventilation. In the supine position, FRC and respiratory
compliance decrease more with an increased body mass index (BMI). In morbidly obese patients
general anaesthesia and paralysis lead to even more atelectasis and an increased risk of
hypoxemia. In about 90 % of all patients ventilated without positive end-expiratory pressure
(PEEP) atelectases are formed, which contribute to impairment of gas exchange. Atelectasis
formation can be reduced by PEEP but increasing intrathoracic pressure with PEEP, impairs
the venous return to the heart, which reduces stroke volume and cardiac output.
In previous studies the investigators compared the effects of increased tidal volume (VT)
with zero end-expiratory pressures (ZEEP) on oxygenation and arterial concentrations of
sevoflurane. The investigators found moderately improved oxygenation and a reduced
difference between arterial and exhaled carbon dioxide tension with larger tidal volumes
achieved this way. The results were similar to what could be expected from an increase in
FRC and also included a more efficient uptake of sevoflurane. The investigators have
recently confirmed these findings also in overweight patients.
In the present study the investigators will compare arterial concentration of sevoflurane
and oxygen in patients with BMI over 25 kg/m2 undergoing abdominal surgery, ventilated with
larger tidal volumes or added 10 cmH2O PEEP. The investigators also will assess the
influence of these ventilation modes on cardiac output.
Method Ethical approval for this study according to the standards set in the Helsinki
declaration (Regional Ethics Committee Dnr: 2009/529 and additions to the application with
the measurement of cardiac output Dnr 2010/481) will be provided by Regional Ethics
Committee, Lund, Sweden on September 2009 and September 2010. The investigation will include
60 patients, ASA physical status 1 or 2, scheduled for elective colon surgery. Patients will
be considered for inclusion in the trial if they will be over 18 yr age and have a BMI more
than 25 kg/m2. All procedures will be estimated to last more than 60 minutes. Consent to
participate in the study will be received from each patient. Patients with known pulmonary
or cardiovascular disease will be excluded. Patients will be randomised to one of two groups
with 30 patients in each group via randomly mixed sealed envelope assignment at the start of
the procedure in the operating theatre. Interim analysis will be performed after 15 + 15
patients.
Experimental procedure Before start of anaesthesia, an unused carbon dioxide absorber will
be applied (Drägersorb, Dräger Medical, Lübeck, Germany) to the anaesthesia ventilator
(Dräger Primus™, Dräger Medical, Lübeck, Germany). All patients will be preoxygenated with
100% oxygen for 3-4 minutes with a fresh gas flow of 5 liters/minute. Anaesthesia will be
induced with 2 µg/kg fentanyl and 1.5-3.0 mg/kg propofol. Rocuronium 0.6 mg/kg will be
administered for muscle paralysis. Ventilation will be assisted manually with 100% oxygen
via a semiopen circle system (4.5 L volume) until tracheal intubation and then by means of a
ventilator with an FiO2 at 0.35 in nitrogen. The respiratory rate will be 15/min throughout
the study and VT will be adjusted as to achieve a PETCO2 at 4.5 kPa. No positive
end-expiratory pressure (PEEP) will be applied. Propofol 8 mg/kg/h will be infused until an
arterial cannula have been inserted in the radial artery. Stroke volume (SV) and cardiac
output (CO) will be assessed in 20 patients (10 in each group) with LIDCO Rapid® (LiDCO Ltd,
Cambridge, UK). Transoesophageal echocardiography (TEE) will be used to assess cardiac
output in 6 patients (3 in each group) with Philips CX-50®, TEE ultrasound X7-2t (Philips
Ultrasound, Bothell, WA, USA). After a control (time zero) sample of arterial blood (3 ml)
have been obtained, the ventilatory mode will be altered as follows: In the group with
increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then
VT will be increased until Pplateau will be 0.04 cm H2O/kg over the initial Pplateau. The
PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose (disposable plastic
tube, Medcore, AB Uppsala, Sweden) placed between the Y-piece of the anaesthesia circle
system and the heat and moisture filter (HME) attached to the endotracheal tube. This
flexible corrugated hose increased the dead-space volume and provided adjustable rebreathing
of carbon dioxide. In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be
applied. When required, VT will be then adjusted to maintain PETCO2at 4.5 kPa. In both
groups, inspiratory:expiratory ratio was 1:2 including an inspiratory plateau of 10%. When
PETCO2 values will be stable at 4.5 kPa, sevoflurane administration will be started with a
vaporiser (sevoflurane Dräger Vapor 2000: Medical, Lübeck, Germany) set to 3%. After 5
minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting
throughout the anaesthesia period.
Blood samples of 3 ml were drawn from the arterial line into heparinised syringes at 1, 3,
5, 10, 15, 30, 45 and 60 minutes after the start of the sevoflurane administration (totally
27 ml). Arterial oxygen tension (PaO2), oxygen saturation (SaO2) and carbon dioxide tension
(PaCO2) will be analysed using an automatic blood gas analyzer (ABL 725™, Radiometer,
Copenhagen Denmark). Sevoflurane concentration will be analysed with gas chromatography (GC)
on a Perkin-Elmer 3920 gas liquid chromatograph, as previously described.
Patients will be monitored with three-lead ECG, heart rate, oxygen saturation, as measured
by pulse oximeter (SpO2) and invasive arterial blood pressure (Solar 8000, General Electric
Medical System, Milwaukee, WI, USA). SV and CO were assessed with a LIDCO Rapid® via the
arterial catheter. Inspiratory and expiratory oxygen partial pressure (FiO2, PETO2),
sevoflurane inspiratory and expiratory partial pressure (Fisevo, PETsevo) and carbon dioxide
inspiratory and expiratory partial pressure (FiCO2, PETCO2) will be analysed by the
ventilator. Total ventilation per minute, tidal volumes and airway pressures as peak
pressure, plateau pressure and mean pressure were measured and documented at the same
intervals. Static compliance of the respiratory system will be calculated as tidal volume
divided by the inspiratory plateau pressure minus PEEP.
Extra doses of fentanyl (50-100 µg) will be given if mean arterial blood pressure (MAP)
increased more than 20% above the initial baseline level. Hypotension (MAP less than 60
mmHg) will be treated with 5-10 mg norepinephrine intravenously. All patients received 3-5
ml/kg/h of glucose solution 2.5% with sodium (70 mmol/l), chloride (45 mmol/l) and acetate
(25 mmol/l) intravenously. Neuromuscular blockade will be monitored with a neuromuscular
transmission analyzer (TOF-Watch™; Organon Technology B V., Boxel Netherlands). Additional
doses of rocuronium were given at the discretion of the anaesthetist.
LiDCO The LiDCO System is a cardiac output monitoring apparatus that uses pulse waveform
contour analysis via an arterial catheter. The device uses a proprietary algorithm to
analyze the pulse contour by using patient specific data from the patient monitor.16 Linton
and colleagues found a good conformity between thermodilutions and LiDCO measurements in 40
patients, with a linear regression value of 0.94.
Transoesophageal echocardiography Stroke volume, cardiac output, and right ventricular
function will be assessed using transoesophageal echocardiography. Four and 5-chamber
transgastric views will be obtained in all six patients included for TEE. The velocity time
integral at the left ventricular outflow tract (VTI LVOT) was measured using pulsed wave
Doppler. The diameter of the aorta will be measured using a mid-oesophageal long axis view
at the level of the aortic annulus. Measurement of stroke volume will be made by multiplying
the LVOT VTI and the aortic diameter. Cardiac output will be calculated by multiplying
stroke volume with heart rate. All images will be recorded in triplicate by the same
operator and measurements made off-line in a blinded fashion.
;
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |